Trial Profile
An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Mar 2022
Price :
$35
*
At a glance
- Drugs Padsevonil (Primary)
- Indications Epilepsy; Seizures
- Focus Adverse reactions; Therapeutic Use
- Sponsors UCB Biopharma
- 30 Nov 2021 Status has been changed to discontinued.
- 05 Mar 2021 This trial has been discontinued in Portugal, according to European Clinical Trials Database record. (Global end date: 2020-05-21)
- 07 Jan 2021 This trial has been discontinued in Germany according to European clinical trials database record.